HOME >> BIOLOGY >> NEWS
Stronger therapy better for AML with normal genetics

COLUMBUS, Ohio New research is helping select which therapies improve the chances of remission in the largest category of people affected by acute myeloid leukemia (AML) those whose cancer cells have normal-looking chromosomes.

The findings suggest that people receiving more intense therapies are more likely to enter remission and to remain there longer than those receiving lower-dose therapies.

The study was published online Nov. 8 by the Journal of Clinical Oncology.

The Cancer and Leukemia Group B (CALGB) study was initiated by researchers at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSU CCC-James). It is part of a larger CALGB cytogenetic trial chaired by Clara D. Bloomfield, professor of internal medicine and the William G. Pace III Professor in Cancer Research, OSU Cancer Scholar and senior adviser to the OSU cancer program.

Unexpectedly, the current study also found that patients who had an enlarged spleen at the time of their initial treatment were less likely to enter remission. AML patients are in remission when leukemic cells are not microscopically detectable among their bone-marrow cells.

"These preliminary findings raise the question of whether additional treatment directed specifically to the spleen might improve remission rates," says first author Sherif S. Farag, assistant professor of internal medicine and a medical oncologist with the OSU CCC-James. "At this point, this is just a hypothesis that needs to be tested, but it may be that the spleen is a sanctuary site for leukemic cells and needs separate treatment."

A diagnosis of AML routinely includes studying patients' leukemic cells for chromosome damage, a process known as cytogenetic analysis. The information helps determine the best therapy and a patient's chance of remission and cure. But 40 percent of AML patients have leukemic cells wit
'"/>

Contact: Darrell E. Ward
Ward-15@medctr.osu.edu
614-293-3737
Ohio State University
29-Nov-2004


Page: 1 2 3

Related biology news :

1. Stronger evidence found linking Epstein-Barr virus and risk of multiple sclerosis
2. Testosterone replacement therapy: How safe for aging men?
3. Progesterone therapy and preterm birth: More evidence helps identify women who can benefit
4. Aggressive therapy best for certain AML patients
5. Under magnetic force, nanoparticles may deliver gene therapy
6. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
7. Stem cell therapy rescues motor neurons in ALS model
8. Study identifies new gene therapy tools for inherited blindness
9. Breast cancer and hormone therapy -- A looking-glass mirror?
10. Radiation therapy combined with microsurgery shows promise for curing injured spinal cord
11. Nodal status is best predictor of outcome after neoadjuvant therapy for esophageal cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/15/2017)... , Aug. 15 2017   ivWatch LLC , a ... intravenous (IV) therapy, today announced receipt of its ISO 13485 Certification, ... by the International Organization for Standardization (ISO®). ... ivWatch Model 400 Continuous Monitoring device for the early ... "This is an ...
(Date:7/20/2017)... (NYSE: DAL ) customers now can use fingerprints instead of ... Airport (DCA). ... Delta launches biometrics to board aircraft at Reagan Washington National Airport ... Delta,s biometric boarding pass experience that launched in May ... boarding process to allow eligible Delta SkyMiles Members who are enrolled in ...
(Date:6/30/2017)... Va. , June 30, 2017 ... leading developer and supplier of face and eye ... ATA Featured Product provider program. ... an innovative way to monitor a driver,s attentiveness ... greatly from being able to detect fatigue and ...
Breaking Biology News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017 After spending the past two ... with crowdsourced data collection, GeneFo now offers this platform to healthcare ... and amplifying support, adherence, and data collection vis a vis their ... mark the successful launch of this offer. ... GeneFo ...
(Date:8/15/2017)... ... August 15, 2017 , ... Kenall, a leader in ... to stay tightly sealed and perform efficiently for years. The downlights are ideal ... just aren't enough, such as: hospitals; behavioral health facilities; cleanrooms; containment areas; food ...
(Date:8/14/2017)... Portland, Oregon (PRWEB) , ... August 14, 2017 ... ... modules that provide essential device-to-computer interconnect using USB or PCI Express, announced the ... hardware. , SYZYGY is intended to satisfy the need for a compact, low ...
(Date:8/11/2017)... ... August 11, 2017 , ... ... and, in particular, more natural alternatives to synthetic ingredients,” said Matt Hundt, President ... Wave, with the established manufacturing presence and know-how of Biorigin will allow us ...
Breaking Biology Technology:
Cached News: